Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
MeSH Number(s)
E05.318.760.535.220
E05.337.250.220
N05.715.360.775.235.220
N06.850.520.450.535.220
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in Harvard Catalyst Profiles by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 0 | 1 | 1 |
1994 | 1 | 1 | 2 |
1995 | 1 | 0 | 1 |
1996 | 1 | 1 | 2 |
1997 | 1 | 3 | 4 |
1998 | 1 | 2 | 3 |
1999 | 1 | 2 | 3 |
2000 | 0 | 3 | 3 |
2001 | 0 | 10 | 10 |
2002 | 3 | 6 | 9 |
2003 | 2 | 3 | 5 |
2004 | 4 | 7 | 11 |
2005 | 2 | 14 | 16 |
2006 | 3 | 11 | 14 |
2007 | 0 | 12 | 12 |
2008 | 5 | 23 | 28 |
2009 | 4 | 15 | 19 |
2010 | 4 | 17 | 21 |
2011 | 2 | 24 | 26 |
2012 | 6 | 20 | 26 |
2013 | 10 | 18 | 28 |
2014 | 8 | 19 | 27 |
2015 | 0 | 19 | 19 |
2016 | 6 | 23 | 29 |
2017 | 5 | 32 | 37 |
2018 | 9 | 33 | 42 |
2019 | 5 | 35 | 40 |
2020 | 1 | 37 | 38 |
2021 | 4 | 31 | 35 |
2022 | 1 | 25 | 26 |
2023 | 0 | 2 | 2 |
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
Fat digestion using RELiZORB in children with short bowel syndrome who are dependent on parenteral nutrition: Protocol for a 90-day, phase 3, open labeled study. PLoS One. 2023; 18(3):e0282248.
-
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat Commun. 2023 01 19; 14(1):331.
-
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 12 27; 6(24):6140-6150.
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
-
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. Clin Lymphoma Myeloma Leuk. 2022 10; 22 Suppl 2:S335-S336.
-
A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID. Trials. 2022 Sep 15; 23(1):782.
-
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Oct; 18(33):3689-3699.
-
Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy. Am J Cardiol. 2022 11 15; 183:93-98.
-
Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis. J Urol. 2022 10; 208(4):838-845.
-
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncol. 2022 Oct; 18(31):3481-3492.